Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.20.

Several brokerages recently issued reports on EYPT. Chardan Capital lifted their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Citigroup boosted their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, HC Wainwright boosted their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 5th.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares during the last quarter. California State Teachers Retirement System grew its holdings in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth approximately $76,000. Finally, Persistent Asset Partners Ltd bought a new stake in Eyepoint Pharmaceuticals during the 4th quarter worth approximately $98,000. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Trading Down 2.2%

Shares of Eyepoint Pharmaceuticals stock opened at $13.11 on Tuesday. The firm has a market capitalization of $1.09 billion, a PE ratio of -4.15 and a beta of 1.89. The firm’s 50 day moving average is $14.38 and its 200 day moving average is $14.51. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.03). The company had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.01 million. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. As a group, research analysts anticipate that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.